 |
|
Home | Sarepta Therapeutic Upgraded by Piper Jaffray to “Neutral” (SRPT) |
 |
Sarepta Therapeutic Upgraded by Piper Jaffray to “Neutral” (SRPT)
|
 |
- December 23, 2013
-
Sarepta Therapeutic (NASDAQ:SRPT) was upgraded by stock analysts at Piper Jaffray from an “underweight” rating to a “neutral” rating in a report issued on Monday, TheFlyOnTheWall.com reports. The firm currently has a $20.00 target price on the stock, up from their previous target price of $19.55. Piper Jaffray’s target price would indicate a potential upside […]This article (Sarepta Therapeutic Upgraded by Piper Jaffray to “Neutral” (SRPT)) was originally developed by and is property of American Banking News.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
- Read more at:http://www.americanbankingnews.com/2013/12/23/sarepta-therapeutic-upgraded-by-piper-jaffray-to-neutral-srpt/
|
 |
|
 |
|
 |
